Covid-19 and Parkinson's disease: an overview.
Covid-19
Movement disorders
Parkinson’s disease
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
29
12
2020
accepted:
20
07
2021
revised:
26
06
2021
pubmed:
28
7
2021
medline:
5
11
2021
entrez:
27
7
2021
Statut:
ppublish
Résumé
In March 2020, WHO declared Covid-19 outbreak pandemic. There has been increasing evidence that frail, old, multi-pathological patients are at greater risk of developing severe Covid-19 infection than younger, healthy ones. Covid-19's impact on Parkinson's Disease (PD) patients could be analysed through both the influence on PD patients' health and their risk of developing severe Covid-19, and the consequences of lockdown and restrictive measures on mental and cognitive health on both patients and caregivers. Moreover, there are critical issues to be considered about patients' care and management through an unprecedented time like this. One important issue to consider is physiotherapy, as most patients cannot keep exercising because of restrictive measures which has profoundly impacted on their health. Lastly, the relationship between PD and Sars-Cov2 may be even more complicated than it seems as some studies have hypothesized a possible Covid-19-induced parkinsonism. Hereby, we review the state of the art about the relationship between Covid-19 and Parkinson's Disease, focusing on each of these five points.
Identifiants
pubmed: 34313818
doi: 10.1007/s00415-021-10721-4
pii: 10.1007/s00415-021-10721-4
pmc: PMC8313415
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
4415-4421Informations de copyright
© 2021. Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC (2020) Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 324(8):782–793. https://doi.org/10.1001/jama.2020.12839
doi: 10.1001/jama.2020.12839
pubmed: 32648899
Meng L et al (2020) Intubation and ventilation amid the COVID-19 outbreak: Wuhan’s experience. Anesthesiology. https://doi.org/10.1097/ALN.0000000000003296
doi: 10.1097/ALN.0000000000003296
pubmed: 32928121
pmcid: 7491163
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Yu T (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 395(10223):507–13
doi: 10.1016/S0140-6736(20)30211-7
Harenberg J, Favaloro E (2020) COVID-19: Progression of disease and intravascular coagulation-present status and future perspectives. Clin Chem Lab Med 58(7):1029–1036. https://doi.org/10.1515/cclm-2020-0502
doi: 10.1515/cclm-2020-0502
pubmed: 32406381
Iba T, Levy JH, Levi M, Thachil J (2020) Coagulopathy in COVID-19. J Thromb Haemost 18(9):2103–2109. https://doi.org/10.1111/jth.14975
doi: 10.1111/jth.14975
pubmed: 32558075
Jose RJ, Manuel A (2020) COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med 8(6):e46–e47. https://doi.org/10.1016/S2213-2600(20)30216-2
doi: 10.1016/S2213-2600(20)30216-2
pubmed: 32353251
Asadi-Pooya AA, Simani L (2020) Central nervous system manifestations of COVID-19: a systematic review. J Neurol Sci. https://doi.org/10.1016/j.jns.2020.116832
doi: 10.1016/j.jns.2020.116832
pubmed: 32299017
pmcid: 7151535
Andalib S et al (2021) Peripheral nervous system manifestations associated with COVID-19. Curr Neurol Neurosci Rep 21(3):2021. https://doi.org/10.1007/s11910-021-01102-5
doi: 10.1007/s11910-021-01102-5
Merello M, Bhatia KP, Obeso JA (2021) SARS-CoV-2 and the risk of Parkinson’s disease: facts and fantasy. Lancet Neurol 20(2):94–95. https://doi.org/10.1016/S1474-4422(20)30442-7
doi: 10.1016/S1474-4422(20)30442-7
pubmed: 33253627
Bhidayasiri R, Virameteekul S, Kim J-M, Pal PK, Chung S-J (2020) COVID-19: an early review of its global impact and considerations for Parkinson’s Disease patient care. J Movement Disord. https://doi.org/10.14802/jmd.20042/J
doi: 10.14802/jmd.20042/J
Antonini A, Leta V, Teo J, Chaudhuri KR (2020) Outcome of Parkinson’s disease patients affected by COVID-19. Movement Disord 35(6):905–908. https://doi.org/10.1002/mds.28104
doi: 10.1002/mds.28104
pubmed: 32347572
Ait Wahmane S, Achbani A, Ouhaz Z, Elatiqi M, Belmouden A, Nejmeddine M (2020) The possible protective role of α-Synuclein against severe acute respiratory syndrome Coronavirus 2 infections in patients with Parkinson’s Disease. Movement Disord 35(8):1293–1294. https://doi.org/10.1002/mds.28185
doi: 10.1002/mds.28185
pubmed: 32519352
Sulzer D et al (2020) COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside. NPJ Parkinson’s Disease. https://doi.org/10.1038/s41531-020-00123-0
doi: 10.1038/s41531-020-00123-0
pubmed: 32885037
pmcid: 7441399
Cilia R et al (2020) Effects of COVID-19 on Parkinson’s Disease clinical features: a community-based case-control study. Mov Disord 35(8):1287–1292. https://doi.org/10.1002/mds.28170
doi: 10.1002/mds.28170
pubmed: 32449528
Fasano A et al (2020) Management of advanced therapies in parkinson’s disease patients in times of humanitarian crisis: The COVID-19 experience. Movement Disord Clin Pract 7(4):361–372. https://doi.org/10.1002/mdc3.12965
doi: 10.1002/mdc3.12965
Fasano A et al (2020) Predictors of COVID-19 outcome in Parkinson’s disease. Park Relat Disord 78:134–137. https://doi.org/10.1016/j.parkreldis.2020.08.012
doi: 10.1016/j.parkreldis.2020.08.012
Del Prete E et al (2020) Prevalence and impact of COVID-19 in Parkinson’s disease: evidence from a multi-center survey in Tuscany region. J Neurol. https://doi.org/10.1007/s00415-020-10002-6
doi: 10.1007/s00415-020-10002-6
pubmed: 32880722
pmcid: 7471534
Artusi CA et al (2020) COVID-19 in Parkinson’s disease: report on prevalence and outcome. Parkinsonism Relat Disord 80:7–9. https://doi.org/10.1016/j.parkreldis.2020.09.008
doi: 10.1016/j.parkreldis.2020.09.008
pubmed: 32920322
pmcid: 7474816
Artusi CA et al (2021) COVID-19 and Parkinson’s disease: what we know so far? J Dis Parkinsons. https://doi.org/10.3233/jpd-202463
doi: 10.3233/jpd-202463
Fasano A et al (2020) COVID-19 in Parkinson’s Disease Patients Living in Lombardy, Italy. Mov Disord 35(7):1089–1093. https://doi.org/10.1002/mds.28176
doi: 10.1002/mds.28176
pubmed: 32484584
Smieszek S, Przychodzen B, Polymeropoulos M (2020) Amantadine disrupts lysosomal gene expression; potential therapy for COVID19. BioRxiv. https://doi.org/10.1101/2020.04.05.026187
doi: 10.1101/2020.04.05.026187
Kobylecki C, Jones T, Lim CK, Miller C, Thomson AM (2020) Phenomenology and outcomes of in-patients with parkinson’s disease during the Coronavirus Disease 2019 pandemic. Movement Disord 35:1295–1296. https://doi.org/10.1002/mds.28205
doi: 10.1002/mds.28205
pubmed: 32583481
Cubo E, Hassan A, Bloem BR, Mari Z (2020) Implementation of telemedicine for urgent and ongoing healthcare for patients with Parkinson’s disease during the COVID-19 pandemic: new expectations for the future. J Parkinson’s Dis 10(3):911–913. https://doi.org/10.3233/JPD-202108
doi: 10.3233/JPD-202108
Cheong JLY, Goh ZHK, Marras C, Tanner CM, Kasten M, Noyce AJ (2020) The impact of COVID-19 on access to Parkinson’s disease medication. Mov Disord 35(12):2129–2133. https://doi.org/10.1002/mds.28293
doi: 10.1002/mds.28293
pubmed: 32860226
Miocinovic S et al (2020) Recommendations for Deep brain stimulation device management during a pandemic. J Parkinson’s Dis. https://doi.org/10.3233/JPD-202072
doi: 10.3233/JPD-202072
van der Kolk NM et al (2015) Design of the Park-in-Shape study: A phase II double blind randomized controlled trial evaluating the effects of exercise on motor and non-motor symptoms in Parkinson’s disease. BMC Neurol. https://doi.org/10.1186/s12883-015-0312-6
doi: 10.1186/s12883-015-0312-6
pubmed: 25880966
pmcid: 4418070
Van De Wetering-Van Dongen VA, Kalf JG, Van Der Wees PJ, Bloem BR, Nijkrake MJ (2020) The effects of respiratory training in Parkinson’s disease: a systematic review. J Parkinson’s Dis. https://doi.org/10.3233/JPD-202223
doi: 10.3233/JPD-202223
Song J, Ahn JH, Choi I, Mun JK, Cho JW, Youn J (2020) The changes of exercise pattern and clinical symptoms in patients with Parkinson’s disease in the era of COVID-19 pandemic. Park Relat Disord 80:148–151. https://doi.org/10.1016/j.parkreldis.2020.09.034
doi: 10.1016/j.parkreldis.2020.09.034
Subramanian I (2020) Virtual Parkinson’s disease support groups in the COVID-19 Era: social connection in the time of social distancing. Movement Disord Clin Pract 7(6):739–740. https://doi.org/10.1002/mdc3.12994
doi: 10.1002/mdc3.12994
Schirinzi T et al (2020) Physical activity changes and correlate effects in patients with Parkinson’s disease during COVID-19 lockdown. Mov Disord Clin Pract 7(7):797–802. https://doi.org/10.1002/mdc3.13026
doi: 10.1002/mdc3.13026
pmcid: 7404747
Srivastav AK, Samuel AJ (2020) E-rehabilitation: one solution for patients with Parkinson’s disease in COVID-19 era. Parkinsonism Relat Disord 75:128–129. https://doi.org/10.1016/j.parkreldis.2020.05.021
doi: 10.1016/j.parkreldis.2020.05.021
pubmed: 32532625
pmcid: 7271872
Shah H, Quinn L, Macpherson C, Long K, Shah H (2020) Promoting physical activity via telehealth in people with Parkinson Disease: the path forward after the COVID-19 pandemic?”. Phys Ther 100:1–7. https://doi.org/10.1093/ptj/pzaa128/5876269
doi: 10.1093/ptj/pzaa128/5876269
Shalash A et al (2020) mental health, physical activity, and quality of life in parkinson’s disease during COVID-19 pandemic. Movement Disord 35(7):1097–1099. https://doi.org/10.1002/mds.28134
doi: 10.1002/mds.28134
pubmed: 32428342
Schirinzi T et al (2020) Self-reported needs of patients with Parkinson’s disease during COVID-19 emergency in Italy. Neurol Sci 41(6):1373–1375. https://doi.org/10.1007/s10072-020-04442-1
doi: 10.1007/s10072-020-04442-1
pubmed: 32363506
Salari M et al (2020) Incidence of anxiety in parkinson’s disease during the coronavirus disease (COVID-19) pandemic. Movement Disord 35(7):1095–1096. https://doi.org/10.1002/mds.28116
doi: 10.1002/mds.28116
pubmed: 32395849
Oppo V et al (2020) Parkinson’s Disease symptoms have a distinct impact on caregivers’ and patients’ stress: a study assessing the consequences of the COVID-19 lockdown. Movement Disord Clin Pract 7(7):865–867. https://doi.org/10.1002/mdc3.13030
doi: 10.1002/mdc3.13030
Palermo G, Tommasini L, Baldacci F, Del Prete E, Siciliano G, Ceravolo R (2020) Impact of Coronavirus Disease 2019 pandemic on cognition in Parkinson’s Disease. Movement Disord 35(10):1717–1718. https://doi.org/10.1002/mds.28254
doi: 10.1002/mds.28254
pubmed: 32776602
Mikhal E. Cohen GY, Roni E, Bettina S-B, Amir J, Maxim I, Rachel BS, Jefri JP, Hanaa G, Volha S, Natan M (2020) A case of Parkinson disease after SARS-CoV-2 infection. Lancet Neurol
Méndez-Guerrero A et al (2020) Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection. Neurology 95(15):e2109–e2118. https://doi.org/10.1212/WNL.0000000000010282
doi: 10.1212/WNL.0000000000010282
pubmed: 32641525
Faber I, Brandão PRP, Menegatti F, de Carvalho Bispo DD, Maluf FB, Cardoso F (2020) Coronavirus disease 2019 and Parkinsonism: a non-post-encephalitic case. Mov Disord 35(10):1721–1722. https://doi.org/10.1002/mds.28277
doi: 10.1002/mds.28277
pubmed: 32815213